Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Personalis, Inc.

Get SEC filing alerts via email and in your feed for Personalis, Inc.

PSNL

Personalis, Inc.

About Personalis, Inc.

Personalis, Inc. develops and markets advanced cancer genomic tests and services for precision oncology, including liquid biopsy and tumor profiling. Its offerings support pharmaceutical research, biomarker discovery, and clinical decision-making. Serving global markets, the company emphasizes high-sensitivity technologies, clinical evidence, and strategic collaborations to enable personalized cancer therapies and improve patient outcomes. Its business model centers on high-quality genomic testing for healthcare providers and biopharmaceutical companies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Personalis, Inc.

1
1
Personalis, Inc. Personalis Reports 25% Revenue Decline and Increased Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Personalis, Inc. Personalis Reports $69.6 Million Revenue for 2025, 18% Decrease from 2024

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Personalis, Inc. Personalis Reports 44% Revenue Decline in Q3 2025, Net Loss Improves

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Personalis, Inc. Personalis Reports 24% Revenue Decline and $20.1 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Personalis, Inc. Personalis Reports $20.6 Million Revenue in Q1 2025, Driven by Pharma Tests and Population Sequencing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Personalis, Inc. Personalis Reports 41% Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments